Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
Author
Abstract
Suggested Citation
DOI: 10.1016/j.socscimed.2015.01.023
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Julia Black, 2005. "The Development of Risk-Based Regulation in Financial Services: Just ‘Modelling Through’?," Chapters, in: Julia Black & Martin Lodge & Mark Thatcher (ed.), Regulatory Innovation, chapter 8, Edward Elgar Publishing.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Stuart Hogarth & Paul Martin, 2021. "The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine," Regulation & Governance, John Wiley & Sons, vol. 15(3), pages 969-986, July.
- Sturdy, Steve, 2022. "Framing utility: Regulatory reform and genetic tests in the USA, 1989–2000," Social Science & Medicine, Elsevier, vol. 304(C).
- Cambrosio, Alberto & Campbell, Jonah & Keating, Peter & Polk, Jessica B. & Aguilar-Mahecha, Adriana & Basik, Mark, 2022. "Healthcare policy by other means: Cancer clinical research as “oncopolicy”," Social Science & Medicine, Elsevier, vol. 292(C).
- Gardner, John & Webster, Andrew, 2016. "The social management of biomedical novelty: Facilitating translation in regenerative medicine," Social Science & Medicine, Elsevier, vol. 156(C), pages 90-97.
- Erik Aarden & Luca Marelli & Alessandro Blasimme, 2021. "The translational lag narrative in policy discourse in the United States and the European Union: a comparative study," Palgrave Communications, Palgrave Macmillan, vol. 8(1), pages 1-9, December.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Juan Carlos Henao & Carmen Eloísa Ruiz López, 2018. "Corrupción en Colombia Tomo 3 Corrupción privada," Books, Universidad Externado de Colombia, Facultad de Derecho, number 1026, march.
More about this item
Keywords
USA; Pharmacogenomics; Personalised medicine; FDA; Pharmaceutical regulation; Neoliberalism; Technocracy; Bioeconomy;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:socmed:v:131:y:2015:i:c:p:255-262. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/wps/find/journaldescription.cws_home/315/description#description .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.